Our People

A great combination of seasoned passionate experts and younger enthusiast skilled colleagues.
We are committed to act in a way that is consistent with our desire to help individuals and physicians confronting bone disease. We want to provide patients the opportunity to return leaving their normal live, maintain their independence and high quality of life.
 


Lorenzo Pradella

Lorenzo Pradella - CEO


Lorenzo has a Master in Biological Sciences obtained at Università degli Studi di Milano with a Postgraduate Qualification in Pharmacology (Ph.D. equivalent). More then 25 years experiences in R&D, Business Development and Venture Capital. He held various senior positions in multinational companies such as Zambon Group SpA and Catalent Inc (formerly part of Cardinal Health Inc.). Lorenzo established licensing and acquisition deals with pharmaceutical, biotech and medtech companies. General Manager of Zcube srl (Research Venture of Zambon Group) from 2008 Lorenzo developed collaborations and investments with major universities hubs in Europe, United States and Israel, as well as with Mission Bay Capital and the California Institute for Quantitative Biosciences (QB3), headquartered on the UCSF Mission Bay campus. Board member of biotech companies including SuppreMol GmbH when acquired by Baxter International Inc. for EUR 200 million in 2015. President of Italy HealthCare Licensing Group (ItalyHLG) 2010-2014 and Honorary President of the Business Development Academy since 2014.



Elena Venturelli

Elena Venturelli - Head of Regulatory & Quality


Senior management experience encompassing a range of disciplines, including human resource management, industrial relations, strategic planning and quality management. Particular expertise in the design, development and implementation of organizational-wide systems and processes to achieve business objectives and regulatory compliance, and to facilitate quality improvement. Strong skills in strategy development, implementation and monitoring; scenario planning methodology; audit and review processes; policy development, project management; process re-engineering; organisational change. Project Management in Clinical trials for medical devices (Clinical strategy for FIM studies , Regulatory Compliance, Study approvals, Contracts, etc.). Due diligence activity on project, products or companies in the medical device area. Reimbursement strategy for new products and dossier preparation Speaker in intensive seminars in the area of medical devices Clinical, Regulatory and Quality Assurance.

Susanna Salvagno

Susanna Salvagno - Chief Medical & Scientific Officer


With 30 years of experience in Orthopaedics and medical devices in the role of Medical Science Director, has built a clear understanding of clinical needs and market opportunities through the development of global strategic medical programs and the involvement of a world-wide Key Opinion Leaders network. One of her main focuses is the promotion of clinical evidence on the benefits of medical devices and dissemination of best clinical practices.



Andrea Cha

Andrea Cha - Chief Operating Officer


More than 15 year experience in the Medical Device Industry with leadership roles in the Operations area.
Knowledge of Global organizations with relevant reporting requirements and multi-year participation to the Senior Management Board with definition of strategic and operative goal for the local organization as well as Roll-out of Corporate and Business Unit strategies.
Deep understanding of the med-tech environment acquired with international projects of product development, manufacturing scale-up, supply chain optimization, ERP implementation and company integration including the due diligence process.
Important exposure and experience over Lean Manufacturing practices and KPI setup Degree in Industrial Engineering and Global Executive MBA, SDA Bocconi



Robert Wright

Robert Wright - Head Sales and Marketing


After graduating with a BSc( Hon) in Biochemistry at Glasgow University I embarked on a career in Healthcare which has spanned over 30 years.
Starting as a pharmaceutical salesperson with Janssen Cilag, a Johnson and Johnson company, I progressed into roles as a hospital specialist with Astra Pharmaceuticals and eventually as a regional manager with A. Menarini.
I then made the transition into medical devices as Regional Manager with DePuy in orthopaedics before moving to Stryker as Sales and Marketing manager for Bone Regeneration in Europe and finished my 12 year career at Stryker as Spine Director , UK.
Moving to Olympus Biotech I was part of the team to set up and establish this new Olympus Franchise in Europe which led onto establishing a new company Celgentek , in Europe with bone morphogenic proteins and launching this therapy into the spinal market.
Joining Merit medical was a change in therapeutic area where I moved into Interventional Oncology and Spine and looked after the UK and Nordic countries.



Diego Ferrari

Diego Ferrari - Chief Financial Officer


Accountant since 1995, after having been associated in important Brescia firms, about ten years ago I founded the firm of which I am a senior partner and in which, right from the start, alongside the technical-fiscal competence, a business consultancy orientation to render services to its customers more oriented towards global support.
My activities of management analysis, financial planning, improvement of the company's organizational issues are appreciated by clients who recognize the Firm as an important partner with whom to share their growth. This recognition often leads me to assume operational roles, as well as in Boards of Statutory Auditors, also in various Boards of Directors. As a professional I am also a Statutory Auditor and Technical Advisor to the Judge.

Claudio Giuliano

Claudio Giuliano


Claudio Giuliano is a player in the venture capital industry since year 2000. Claudio co-founded in 2007 Innogest Capital, a Venture Capital firm with about € 200 Mln under management, and a partner in the Healthcare and Cardiovascular practice at Innogest. Claudio serves as chairman of the VC Committee at the Italian VC and PE association (AIFI) and is part of several private and public bodies involved in start-up and entrepreneurship development. Prior to Innogest, Claudio was - Associate Director at The Carlyle Group (London) - Strategy consultant at Bain&Co (Italy) - Supply Chain Manager at Hewlett-Packard (California and France). Claudio holds a Summa cum Laude Master of Science in Electronic Engineering from Politecnico di Torino (Italy), a Summa cum Laude Diplôme d'études approfondies in Microelectronics from l’Institute Nationale Polytecnique in Grenoble (France) and an MBA from INSEAD (Dean’s List), in Fontainebleau (France).



Lorenzo Pradella

Lorenzo Pradella


Lorenzo has a Master in Biological Sciences obtained at Università degli Studi di Milano with a Postgraduate Qualification in Pharmacology (Ph.D. equivalent). More then 25 years experiences in R&D, Business Development and Venture Capital. He held various senior positions in multinational companies such as Zambon Group SpA and Catalent Inc (formerly part of Cardinal Health Inc.). Lorenzo established licensing and acquisition deals with pharmaceutical, biotech and medtech companies. General Manager of Zcube srl (Research Venture of Zambon Group) from 2008 Lorenzo developed collaborations and investments with major universities hubs in Europe, United States and Israel, as well as with Mission Bay Capital and the California Institute for Quantitative Biosciences (QB3), headquartered on the UCSF Mission Bay campus. Board member of biotech companies including SuppreMol GmbH when acquired by Baxter International Inc. for EUR 200 million in 2015. President of Italy HealthCare Licensing Group (ItalyHLG) 2010-2014 and Honorary President of the Business Development Academy since 2014.



Diogo Moreira-Rato

Diogo Moreira-Rato


Non-Executive Board Member.
He holds a degree in Marketing & Finance and has titles in Global Strategy & Negotiation and others. During the 16+ years Diogo spent at Johnson & Johnson he became President EMEA for DePuy. He then joined Smith & Nephew as Group President Europe & Canada. Since retiring in 2016 he has been elected to various Non Executive Director positions and is a Managing Partner for Prosperon Ventures.



Alastair Clemow

Alastair Clemow


Non-Executive Board Member.
He holds a PhD and an MBA. In 1981 Alastair joined Johnson & Johnson becoming VP Worldwide Business Development for Ethicon. In 2000, he became President, Board Member and CEO of various Orthopaedic and Spine companies which were sold successfully. He is now Board Member of First Wave Technologies and Chairman of the Board of Ensemble Orthopaedics.



Francesca Natali

Francesca Natali


Shareholder and board member at META Group (MG).
From 2005 she is a Managing Director of META Ventures (MV), the financial company of META Group managing in Italy Poland and Slovenia public-private co-investment risk capital funds. She has a deep experience knowledge on key features and regulation of EU financial instruments, having worked for the European Commission and other important international donors (EIB).



Francesco Granata

Francesco Granata


He was Executive Vice President and Member of the Executive Committee of Biogen Idec (NASDAQ: BIIB).
Previously he was Group Vice President and President of Schering-Plow Europe and Canada, executive positions at Pfizer and CEO at Pharmacia and Dompè Biotec. Currently he sits on the boards of Neopharmed Gentili, Italfarmaco, Diadem and Greenbone. He is a Board Member of the Helsinn Group in Switzerland, a member of the Board and the Investment Committee of the 3B Future Fund (venture capital fund focused on oncology) in Luxembourg.



Roberto De Ponti

Roberto De Ponti


Managing Director and General Partner.
Prior to this, Roberto was Head of Corporate Business Development at Helsinn. Roberto has held several Senior Director positions in various pharmaceutical companies including Pfizer, Indena, Pharmacia & Upjohn, Nerviano Medical Sciences and Boehringer Mannheim. Roberto is on the board of several portfolio companies in Europe and the US. He holds a PharmD degree and is an EU Qualified Person. Roberto serves on the board of Fore Biotherapeutics, GreenBone Ortho S.p.A., iOnctura and OncoResponse Inc.


Giannoudis

Professor Peter Giannoudis

Professor and Chairman within Academic Department of Trauma and Orthopaedic Surgery / Honorary Orthopaedic and Trauma Consultant, Chair of Trauma & Orthopaedic Surgery at the University of Leeds.



Volker Alt

Prof. Volker Alt

Director and Chairman Department of Trauma Surgery University Hospital Regensburg, Germany.



Thierry Bégué

Prof. Thierry Bégué

Chairman, Senior consultant Surgeon, Senior Professor Department of Orthopaedic, Trauma and Reconstructive Surgery Antoine Beclere Hospital, University Paris South (XI) Clamart, France.



Hans-Christoph Pape

Prof. Hans-Christoph Pape

Professor and Chairman of the Department of Trauma Surgery at University Hosptial Zürich, Switzerland.



Michael Plecko

Prof. Michael Plecko

Prim.MR.Dr.med. AUVA Trauma Hospital Graz, Austria Teaching Hospital of Medical University Graz (MEDUNI) Head of Department Orthopaedics and Traumatology GösIngerstrasse 24 A-8020 Graz.



Theodorus Tosonoudis

Dr. Theodorus Tosonoudis

Ass Professor of Orthopaedic Surgery at the University of Crete, Greece.



 

Caution

 

You are entering an area containing information intended for healthcare professionals. If you are a healthcare professional, click here to continue.

 

 

Continue

GreenBoneTM Bone Substitute received CE mark approval